+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 85Years
All Genders
Healthy Volunteers
ID07787182

Evaluation of LY4405094 Safety and Effects in Healthy Volunteers and Alzheimers Disease Patients with Placebo Control

Led by Eli Lilly and Company · Updated on 2026-10-22

68

Participants Needed

18

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating LY4405094, a drug being studied for safety and how it enters the bloodstream, in both healthy participants and those with Alzheimers Disease. The study aims to understand how much and how quickly LY4405094 reaches the bloodstream and brain fluid, while also assessing levels of a specific Alzheimers-related protein in the brain. This is a Phase 1 trial that includes a placebo comparison and uses both intravenous IV and subcutaneous SC administration methods. Participants are assigned randomly to receive either LY4405094 or a placebo, given by IV or SC in healthy volunteers and by IV in participants with Alzheimers Disease. The study includes a single-ascending dose group and a multiple-ascending dose group. Those with Alzheimers will also undergo amyloid positron emission tomography PET scans using Florbetapir F 18 or Florbetaben F 18 to assess amyloid plaque levels. Study stays include a 4-day clinical research unit visit for healthy volunteers and a 3-day stay for Alzheimers participants. During the study, researchers monitor participants for serious adverse events related to the study drug over up to 25 weeks. They also measure drug concentration levels in blood and cerebrospinal fluid, and track amyloid plaque changes using PET scans. Participants will undergo clinical stays, blood tests, scans, and safety monitoring throughout the study period, which lasts up to 13 weeks for healthy volunteers and 25 weeks for those with Alzheimers Disease.

CONDITIONS

Brief Title

A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

Research Team

T

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

P

Physicians interested in becoming principal investigators please contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here